학술논문
Daratumumab combinations for patients with newly diagnosed and relapsed multiple myeloma.
Document Type
Academic Journal
Author
Popat R; University College London Hospitals NHS Foundation Trust, London NW1 2BU, UK; Cancer Institute, University College London, London, UK. Electronic address: rakesh.popat@ucl.ac.uk.; Chavda SJ; University College London Hospitals NHS Foundation Trust, London NW1 2BU, UK; Cancer Institute, University College London, London, UK.
Source
Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE
Subject
Language
English
Abstract
Competing Interests: RP has received grants from GSK, paid to the University of Leeds, UK; consulting fees from Janssen, GSK, and Roche; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Janssen, Bristol Myers Squibb, Sanofi, GSK, and Pfizer; and funds for travel or attendance at meetings from Janssen and GSK. SJC declares no competing interests.